Dysbiosis and Gut Microbiota Modulation in Systemic Sclerosis

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorSchool of Medicine Dr Paulo Prata-
Autor(es): dc.contributorInternal Medicine Graduate Program-
Autor(es): dc.contributorDivision of Clinical Immunology-
Autor(es): dc.contributorUniversidade de São Paulo (USP)-
Autor(es): dc.contributorMicrobiology Program-
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.creatorLemos, Maria Paula Calil-
Autor(es): dc.creatorZucoloto, Talita Graminha-
Autor(es): dc.creatorOliveira, Maria Carolina-
Autor(es): dc.creatorDe Oliveira, Gislane Lelis Vilela-
Data de aceite: dc.date.accessioned2025-08-21T19:16:03Z-
Data de disponibilização: dc.date.available2025-08-21T19:16:03Z-
Data de envio: dc.date.issued2022-04-29-
Data de envio: dc.date.issued2022-04-29-
Data de envio: dc.date.issued2022-03-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1097/RHU.0000000000001748-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/230430-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/230430-
Descrição: dc.descriptionGastrointestinal (GI) involvement is an early manifestation in systemic sclerosis (SSc), affecting more than 90% of patients, and severe GI disease is a marker of poor prognosis and mortality. Recent studies have hypothesized that alterations of the intestinal microbiota, known as dysbiosis, may represent 1 of the possible environmental factors influencing SSc disease status. In addition, specific microorganisms may be associated with SSc pathogenesis, progression, and GI manifestations. Therapeutic approaches aiming to modulate the intestinal microbiota have emerged, as alternatives to treat GI symptoms, and dietary interventions, probiotic administration, and fecal microbiota transplantation are potential therapies for SSc patients. However, given the complexity and variability of pathogenesis and clinical manifestations in SSc, these therapies need to be combined with additional interventions that target other disease components. Here, we summarize studies addressing intestinal dysbiosis in SSc and discuss the potential of microbiota modulators to treat SSc-related GI disorders.-
Descrição: dc.descriptionMicrobiome Study Group School of Medicine Dr Paulo Prata-
Descrição: dc.descriptionInternal Medicine Graduate Program-
Descrição: dc.descriptionDivision of Clinical Immunology-
Descrição: dc.descriptionCenter for Cell-Based Therapy Ribeirão Preto Medical School University of São Paulo-
Descrição: dc.descriptionMicrobiology Program-
Descrição: dc.descriptionDepartment of Food Engineering and Technology Institute of Biosciences Humanities and Exact Sciences São Paulo State University, São José do Rio Preto-
Descrição: dc.descriptionDepartment of Food Engineering and Technology Institute of Biosciences Humanities and Exact Sciences São Paulo State University, São José do Rio Preto-
Formato: dc.format568-573-
Idioma: dc.languageen-
Relação: dc.relationJournal of Clinical Rheumatology-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectdietary interventions-
Palavras-chave: dc.subjectfecal microbiota transplantation-
Palavras-chave: dc.subjectgastrointestinal manifestations-
Palavras-chave: dc.subjectintestinal dysbiosis-
Palavras-chave: dc.subjectmicrobiota-
Palavras-chave: dc.subjectprobiotics-
Palavras-chave: dc.subjectsystemic sclerosis-
Título: dc.titleDysbiosis and Gut Microbiota Modulation in Systemic Sclerosis-
Tipo de arquivo: dc.typevídeo-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.